Comparing Olanzapine and Mirtazapine in the Improvement of Unintentional Weight Loss for Patients with Advanced Stage Cancer
Part of paid clinical trials in Englewood, New Jersey.
- Sponsor
- Englewood Hospital and Medical Center
- Study ID
- NCT05170919
- Phase
- PHASE2
- Status
- Enrolling By Invitation
Conditions
- Anorexia Nervosa with Significantly Low Body Weight
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Mirtazapine — DRUGPatients will be prescribed a dosage of 15 mg per day. Dose will not be escalated.
- Olanzapine — DRUGthe participant will be prescribed a dosage of 2.5mg per day if \> 65 yrs. and 5 mg/per day if \<65 yrs. per day. Per physician discretion, participants are allowed a dose escalation of a maximum of 10mg.
Study Details
To determine whether olanzapine or mirtazapine is more effective in preventing weight loss and appetite loss in cancer patients.
Key Dates
- Start date
- Jan 20, 2022
- Status verified
- Sep 2024
- Primary completion
- Dec 31, 2026
- Completion
- Dec 31, 2026
Study Design
- Enrollment
- 170 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Olanzapine
- Experimental: Mirtazapine
Primary Outcome Measure
Weight [ Time Frame: 6 months ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Englewood Health | Englewood | New Jersey | 07631 | - |
Find similar trials in Englewood, NJ
By research site